Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078526 | 0.91 | USP2 (0.38) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL2300117 | 0.88 | USP2 (0.37) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL2077846 | 0.87 | USP2 (0.36) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL2076816 | 0.86 | USP2 (0.36) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL2078617 | 0.85 | USP2 (0.39) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL2077496 | 0.80 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL12427582 | 0.79 | ADORA2A (0.31) | ADORA2AADORA1 | |
| SCHEMBL2076197 | 0.79 | USP2 (0.33) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL13007299 | 0.78 | USP2 (0.37) | USP2ALDH1A1NQO2TP53MAPT | |
| SCHEMBL12428993 | 0.77 | USP2 (0.37) | USP2ALDH1A1NQO2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | USP2 4580/4885ALDH1A1 1266/4885NQO2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.